recombinant egf (regf Search Results


96
Selleck Chemicals recombinant human egf
Recombinant Human Egf, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/recombinant+egf+(regf/SB203580/pm28485157-32-52-62
Average 96 stars, based on 1 article reviews
recombinant human egf - by Bioz Stars, 2026-09
96/100 stars
  Buy from Supplier

95
Miltenyi Biotec hregf
Hregf, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/recombinant+egf+(regf/Human+EGF%2C+premium+grade/bio_rxiv__2024__04__09__585681-177-50-51
Average 95 stars, based on 1 article reviews
hregf - by Bioz Stars, 2026-09
95/100 stars
  Buy from Supplier

94
Bio-Techne corporation recombinant human hb-egf protein
Recombinant Human Hb Egf Protein, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/recombinant+egf+(regf/Recombinant+Human+HB-EGF+Protein/bio-techne+corporation___259-he
Average 94 stars, based on 1 article reviews
recombinant human hb-egf protein - by Bioz Stars, 2026-09
94/100 stars
  Buy from Supplier

93
R&D Systems recombinant rat egf
Recombinant Rat Egf, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/recombinant+egf+(regf/Recombinant+Rat+EGF+Protein/bio_rxiv__2020__11__24__380527-26-6-9
Average 93 stars, based on 1 article reviews
recombinant rat egf - by Bioz Stars, 2026-09
93/100 stars
  Buy from Supplier

99
Abcam human recombinant epidermal growth factor egf
<t>UC2288</t> inhibited EGFR/ERK pathway. ( A-B ) The expression of p-EGFR/EGFR and p-ERK1/2/ERK was examined by western blot. Data are expressed as mean ± SD, n=3. ** p < 0.01 and *** p < 0.001 compared to control. ( C-D ) Pretreatment with epidermal growth factor <t>(EGF),</t> CCK-8 assay was conducted to evaluate the cell viability. Data are expressed as mean ± SD, n=3. ## p < 0.01 compared to the UC2288 (4 µM)-treated group.
Human Recombinant Epidermal Growth Factor Egf, supplied by Abcam, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/recombinant+egf+(regf/Recombinant+human+Growth+Hormone+protein/pmc07797659-23-4-13
Average 99 stars, based on 1 article reviews
human recombinant epidermal growth factor egf - by Bioz Stars, 2026-09
99/100 stars
  Buy from Supplier

90
R&D Systems egf
<t>UC2288</t> inhibited EGFR/ERK pathway. ( A-B ) The expression of p-EGFR/EGFR and p-ERK1/2/ERK was examined by western blot. Data are expressed as mean ± SD, n=3. ** p < 0.01 and *** p < 0.001 compared to control. ( C-D ) Pretreatment with epidermal growth factor <t>(EGF),</t> CCK-8 assay was conducted to evaluate the cell viability. Data are expressed as mean ± SD, n=3. ## p < 0.01 compared to the UC2288 (4 µM)-treated group.
Egf, supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/recombinant+egf+(regf/Mouse+EGF+Antibody/pm31390563-225-274-280
Average 90 stars, based on 1 article reviews
egf - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

90
Strathmann Biotec AG recombinant murine egf
<t>UC2288</t> inhibited EGFR/ERK pathway. ( A-B ) The expression of p-EGFR/EGFR and p-ERK1/2/ERK was examined by western blot. Data are expressed as mean ± SD, n=3. ** p < 0.01 and *** p < 0.001 compared to control. ( C-D ) Pretreatment with epidermal growth factor <t>(EGF),</t> CCK-8 assay was conducted to evaluate the cell viability. Data are expressed as mean ± SD, n=3. ## p < 0.01 compared to the UC2288 (4 µM)-treated group.
Recombinant Murine Egf, supplied by Strathmann Biotec AG, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/recombinant+egf+(regf/recombinant+murine+egf/pm12089360-232-29-31
Average 90 stars, based on 1 article reviews
recombinant murine egf - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

90
GenScript corporation human recombinant epidermal growth factor (egf)
<t>UC2288</t> inhibited EGFR/ERK pathway. ( A-B ) The expression of p-EGFR/EGFR and p-ERK1/2/ERK was examined by western blot. Data are expressed as mean ± SD, n=3. ** p < 0.01 and *** p < 0.001 compared to control. ( C-D ) Pretreatment with epidermal growth factor <t>(EGF),</t> CCK-8 assay was conducted to evaluate the cell viability. Data are expressed as mean ± SD, n=3. ## p < 0.01 compared to the UC2288 (4 µM)-treated group.
Human Recombinant Epidermal Growth Factor (Egf), supplied by GenScript corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/recombinant+egf+(regf/human+egf/pm35320709-243-47-52
Average 90 stars, based on 1 article reviews
human recombinant epidermal growth factor (egf) - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

94
Gold Biotechnology Inc human egf
<t>UC2288</t> inhibited EGFR/ERK pathway. ( A-B ) The expression of p-EGFR/EGFR and p-ERK1/2/ERK was examined by western blot. Data are expressed as mean ± SD, n=3. ** p < 0.01 and *** p < 0.001 compared to control. ( C-D ) Pretreatment with epidermal growth factor <t>(EGF),</t> CCK-8 assay was conducted to evaluate the cell viability. Data are expressed as mean ± SD, n=3. ## p < 0.01 compared to the UC2288 (4 µM)-treated group.
Human Egf, supplied by Gold Biotechnology Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/recombinant+egf+(regf/EGF%2C+Rat/pmc04705856-48-6-11
Average 94 stars, based on 1 article reviews
human egf - by Bioz Stars, 2026-09
94/100 stars
  Buy from Supplier

90
Funakoshi ltd recombinant murine egf
<t>UC2288</t> inhibited EGFR/ERK pathway. ( A-B ) The expression of p-EGFR/EGFR and p-ERK1/2/ERK was examined by western blot. Data are expressed as mean ± SD, n=3. ** p < 0.01 and *** p < 0.001 compared to control. ( C-D ) Pretreatment with epidermal growth factor <t>(EGF),</t> CCK-8 assay was conducted to evaluate the cell viability. Data are expressed as mean ± SD, n=3. ## p < 0.01 compared to the UC2288 (4 µM)-treated group.
Recombinant Murine Egf, supplied by Funakoshi ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/recombinant+egf+(regf/epidermal+growth+factor/pmc02171522-191-42-47
Average 90 stars, based on 1 article reviews
recombinant murine egf - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

94
Gold Biotechnology Inc number: 1150-04-100
<t>UC2288</t> inhibited EGFR/ERK pathway. ( A-B ) The expression of p-EGFR/EGFR and p-ERK1/2/ERK was examined by western blot. Data are expressed as mean ± SD, n=3. ** p < 0.01 and *** p < 0.001 compared to control. ( C-D ) Pretreatment with epidermal growth factor <t>(EGF),</t> CCK-8 assay was conducted to evaluate the cell viability. Data are expressed as mean ± SD, n=3. ## p < 0.01 compared to the UC2288 (4 µM)-treated group.
Number: 1150 04 100, supplied by Gold Biotechnology Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/recombinant+egf+(regf/EGF%2C+Human/bio_rxiv__2025__08__14__670284-198-12-9
Average 94 stars, based on 1 article reviews
number: 1150-04-100 - by Bioz Stars, 2026-09
94/100 stars
  Buy from Supplier

95
R&D Systems respective quantikine elisa kits
a Images of splinted db/db mouse wounds at day 10 post wounding. b Quantification of migrating epithelial tongues from splinted db/db mouse wounds [Error bars correspond to standard deviations from 4 biological specimens with statistical significance assessed using paired 2-way ANOVA followed by Tukey’s multiple comparison testing, * p < 0.05, ** p < 0.01, **** p < 0.0001]. c IHC staining and d quantification of CD31 + cells/mm 2 demonstrating increased number blood vessels with HβCD + EGF treatment [Error bars correspond to standard deviations from four biological specimens with statistical significance assessed using paired student t -test, **** p < 0.0001] (E-epidermis, D-dermis; scale bar = 50 µm). d <t>ELISA</t> demonstrating increased levels of VEGF in splinted db/db mouse wounds upon incorporation of growth factors into HβCD hydrogels [Error bars correspond to standard deviations from four biological specimens with statistical significance assessed using paired 2-way ANOVA followed by Tukey’s multiple comparison testing, * p < 0.05, ** p < 0.01, **** p < 0.0001]. (scale bar = 50 µm).
Respective Quantikine Elisa Kits, supplied by R&D Systems, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/recombinant+egf+(regf/Human+EGF+Quantikine+ELISA+Kit/pmc12480632-177-41-45
Average 95 stars, based on 1 article reviews
respective quantikine elisa kits - by Bioz Stars, 2026-09
95/100 stars
  Buy from Supplier

Image Search Results


UC2288 inhibited EGFR/ERK pathway. ( A-B ) The expression of p-EGFR/EGFR and p-ERK1/2/ERK was examined by western blot. Data are expressed as mean ± SD, n=3. ** p < 0.01 and *** p < 0.001 compared to control. ( C-D ) Pretreatment with epidermal growth factor (EGF), CCK-8 assay was conducted to evaluate the cell viability. Data are expressed as mean ± SD, n=3. ## p < 0.01 compared to the UC2288 (4 µM)-treated group.

Journal: Journal of Cancer

Article Title: UC2288 induces cell apoptosis of nasopharyngeal carcinoma cells via inhibiting EGFR/ERK pathway

doi: 10.7150/jca.48282

Figure Lengend Snippet: UC2288 inhibited EGFR/ERK pathway. ( A-B ) The expression of p-EGFR/EGFR and p-ERK1/2/ERK was examined by western blot. Data are expressed as mean ± SD, n=3. ** p < 0.01 and *** p < 0.001 compared to control. ( C-D ) Pretreatment with epidermal growth factor (EGF), CCK-8 assay was conducted to evaluate the cell viability. Data are expressed as mean ± SD, n=3. ## p < 0.01 compared to the UC2288 (4 µM)-treated group.

Article Snippet: UC2288 (purity ~99%) and human recombinant epidermal growth factor (EGF) were purchased from Abcam (Cambridge, UK), and dissolved in dimethyl sulfoxide (DMSO) and water, respectively.

Techniques: Expressing, Western Blot, CCK-8 Assay

a Images of splinted db/db mouse wounds at day 10 post wounding. b Quantification of migrating epithelial tongues from splinted db/db mouse wounds [Error bars correspond to standard deviations from 4 biological specimens with statistical significance assessed using paired 2-way ANOVA followed by Tukey’s multiple comparison testing, * p < 0.05, ** p < 0.01, **** p < 0.0001]. c IHC staining and d quantification of CD31 + cells/mm 2 demonstrating increased number blood vessels with HβCD + EGF treatment [Error bars correspond to standard deviations from four biological specimens with statistical significance assessed using paired student t -test, **** p < 0.0001] (E-epidermis, D-dermis; scale bar = 50 µm). d ELISA demonstrating increased levels of VEGF in splinted db/db mouse wounds upon incorporation of growth factors into HβCD hydrogels [Error bars correspond to standard deviations from four biological specimens with statistical significance assessed using paired 2-way ANOVA followed by Tukey’s multiple comparison testing, * p < 0.05, ** p < 0.01, **** p < 0.0001]. (scale bar = 50 µm).

Journal: NPJ Regenerative Medicine

Article Title: Scaffolds with spatiotemporally controlled growth factor delivery and cyclodextrin-enabled antagonism of growth factor receptor sequestration promote cutaneous wound healing

doi: 10.1038/s41536-025-00431-0

Figure Lengend Snippet: a Images of splinted db/db mouse wounds at day 10 post wounding. b Quantification of migrating epithelial tongues from splinted db/db mouse wounds [Error bars correspond to standard deviations from 4 biological specimens with statistical significance assessed using paired 2-way ANOVA followed by Tukey’s multiple comparison testing, * p < 0.05, ** p < 0.01, **** p < 0.0001]. c IHC staining and d quantification of CD31 + cells/mm 2 demonstrating increased number blood vessels with HβCD + EGF treatment [Error bars correspond to standard deviations from four biological specimens with statistical significance assessed using paired student t -test, **** p < 0.0001] (E-epidermis, D-dermis; scale bar = 50 µm). d ELISA demonstrating increased levels of VEGF in splinted db/db mouse wounds upon incorporation of growth factors into HβCD hydrogels [Error bars correspond to standard deviations from four biological specimens with statistical significance assessed using paired 2-way ANOVA followed by Tukey’s multiple comparison testing, * p < 0.05, ** p < 0.01, **** p < 0.0001]. (scale bar = 50 µm).

Article Snippet: For determination of growth factor release from the hydrogels, gelatin hydrogels were loaded onto 0.4 μm PET membranes within a 24 well plate, submerged in PBS, and growth factor release quantified at 0, 12, 24, 48, 96 and 120 h using respective Quantikine ELISA kits (R&D Systems, DEG00 for EGF, DBB00 for PDGF-BB, and DVE00 for VEGF).

Techniques: Comparison, Immunohistochemistry, Enzyme-linked Immunosorbent Assay